Distinctive clinic features of pheochromocytoma in the setting of multiple endocrine neoplasia 2A;Feocromocitoma asociado a neoplasia endocrina múltiple 2A y esporádico: Características diferenciales

Medicina Clinica

Volumn 115, Issue 11, 2000, Pages 405-409

  Lecube, Albert ^a   Hernández, Cristina ^a   Oriola, Josep ^b   Tovar, José Luis ^a   Gémar, Enrique ^a   Baena, Juan Antonio ^a   Mesa, Jordi ^a   Simó, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Adrenal; Catecholamines; Hypertension; Multiple endocrine neoplasia 2A; Pheochromocytoma

Indexed keywords

CATECHOLAMINE; VANILMANDELIC ACID;

ADRENAL TUMOR; ADULT; ARTICLE; BLOOD; CALORIMETRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FLUOROMETRY; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PHEOCHROMOCYTOMA; SIPPLE SYNDROME; STATISTICAL ANALYSIS; URINE;

ADRENAL GLAND NEOPLASMS; ADULT; CALORIMETRY; CATECHOLAMINES; DATA INTERPRETATION, STATISTICAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUOROMETRY; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PEDIGREE; PHEOCHROMOCYTOMA; VANILMANDELIC ACID;

EID: 0034618972     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71575-2     Document Type: Article

References (26)

1. Manger WM, Gifford RW. Pheochromocytoma. Nueva York: Springer-Verlag, 1977.
2. Sheps SG, Jiang N-S, Kice GG. Diagnostic evaluation of pheochromocytoma. Endocrinol Metabol Clin North Am 1988; 17: 397-414.
3. Manger WM, Gifford RW. Pheochromocytoma: current diagnosis and management. Clev Clin J Med 1993; 60: 365-378.
4. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531-1538.
5. Ledger GA, Khosla S, Lindor NM, Thibodeau SN, Gharib H. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 1995; 122: 118-124.
6. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-856.
7. Mulligan LM, Kwock JBJ, Healey CS, Elsdon MJ, Eng C, Gardner B et al. Germline mutations of the RET proto-oncogene in MEN type 2A (MEN 2A). Nature 1993; 363: 458-460.
8. Thomas PM, Gagel RF. Advances in genetic screening for multiple endocrine neoplasia type 2 and the implications for management of children at risk. Endocrinologist 1994; 4: 140-146.
9. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham GH, JansenShchillhorn van Veen JM et al. From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. J Intern Med 1995; 238: 347-356.
10. Simón I, Hernández C, Tovar JL, Bonnin J, Simó R, Mesa J. Feocromocitoma: revisión clínica de 21 casos. Med Clin (Barc) 1991; 97: 569-572.
11. Oriola J, Hernández C, Simó R, Barceló A. Casamitjana R, Vilardell E et al. Genetic analysis of seven Mediterranean families with multiple endocrine neoplasia type 2A. Clin Endocrinol 1996; 44: 207-212.
12. Conferencia clinicopatológica: cefalea, tetania y síndrome diarreico en una paciente con MEN II. Endocrinología 1992; 39: 30-42.
13. Casanova S, Rosenberg-Bourgin M, Farkas D, Calmettes C, Feingold N, Heshmati HM et al. Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol 1993; 38: 531-537.
14. Biarnés J, Miranda M, Corral J, Gabau E, Matías-Guiu X, Matilla A et al. Alteraciones moleculares del protooncogén RET en familias con neoplasia endocrina múltiple 2A. Med Clin (Barc) 1996; 107: 321-325.
15. Pomares FJ, Cañas R, Rodríguez JM, Hernández AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol 1998; 48: 195-200.
16. Pomares FJ, Bernabé MJ, Matías-Guiu X, Rodríguez JM, Soriano J, Sola J et al. Análisis genético de las mutaciones de RET en las familias con neoplasia endocrina múltiple tipo 2 de la comunidad de Murcia. Med Clin (Barc) 1999; 112: 646-650.
17. Gagel RF, Tashjian AH, Cummings T, Papathanasopoulos BS, Kaplan MM, DeLettis RA et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience. N Engl J Med 1988; 318: 478-484.
18. Easton DF, Ponder MA, Cummings T, Gagel RF, Hansen HH, Reichlin S et al. The clinical and screening age-at-onset distribution for the MEN 2 syndrome. Am J Hum Genet 1989; 44 : 208-215.
19. Bravo EL, Gifford RW. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298-1303.
20. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Medicine (Baltimore) 1990; 70: 46-66.
21. Bravo EL. Diagnosis of pheochromocytoma. Reflections on a controversy. Hypertension 1991; 17: 742-744.
22. Kaneda N, Ichinose H, Kohayashi K, Oka K, Kishi F, Nakazawa A et al. Molecular cloning of cDNA and chromosomal assignment of the gene for human phenylethanolamine N-methyltransferase, the enzyme for epinephrine biosynthesis. J Biol Chem 1988; 263: 7672.
23. Simó R. Feocromocitoma: diagnóstico de localización mediante métodos no invasivos. Endocrinologia 1991; 38: 51-56.
24. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575-1579.
25. Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R et al. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 1996; 81; 1780-1783.
26. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G et al. Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997; 57: 2870-2872.